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Abstract
Background: Functional dyspepsia (FD) is a gastrointestinal disorder characterized by recurrent and diverse symptoms
and pathophysiology that remains unexplained following routine clinical investigation. Enzynorm®f is a pharmaceutical
preparation comprising fixed amounts of pepsin of biological origin and organically bound acid in the form of amino
acid hydrochloride. It is traditionally used as a mild agent to support gastric function and to stimulate the stomach’s
proteolytic activities in FD.
Methods: In a non-interventional, observational, post-marketing surveillance study, patients with an established diagnosis
of FD were treated with a fixed combination of pepsin and amino acid hydrochloride taken as tablets three times daily
for 6 weeks. The primary objective of this study was to assess the change in symptoms using the validated
Gastrointestinal Symptom Score (GIS©). Secondary objectives included patients’ assessment of their gastrointestinal
symptoms as well as treatment safety and tolerability.
Results: A total of 97 patients (mean age 58.4 ± 13.9 years; 63.2% females) were included in the study, with
72 data having GIS© score data at baseline and at 6 weeks, and 34 also at 3 weeks. The overall GIS© sum
score decreased by 4.1 (p < 0.0001) from 11.6 (±4.8) at baseline to 7.4 (± 4.6) reflecting an improvement of
clinical symptomatology after 6 weeks of treatment. In a subgroup of 70 patients who had FD meeting the
Rome III criteria a GIS© score reduction of ≥50% was observed after 3 weeks treatment in 24% and in 30.8%
after 6 weeks. Adverse events were mostly gastrointestinal in nature and consistent with the underlying disease; no
unexpected adverse reactions were reported. Twenty-seven patients discontinued the study, mostly because
of gastrointestinal symptoms.
Conclusion: The results of this study support the efficacy of a fixed combination of pepsin and amino acid
hydrochloride for the treatment of patients with FD and also suggest good to moderate treatment tolerability. These
findings should be further explored in a randomised, placebo-controlled clinical trial.
Clinical trial registration: This study has been retrospectively registered in the ClinicalTrials.gov registry, trial identifier
NCT03076411.
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Background
Functional dyspepsia (FD) is a gastrointestinal disorder
characterized by recurrent and diverse symptomatology
and pathophysiology [1–3]. According to the Rome III
criteria, symptoms include, but are not limited to post-
prandial fullness, early satiation, epigastric pain, and epi-
gastric burning that remain unexplained following
routine clinical investigation [4]. A number of treatment
approaches are available, including proton pump inhibi-
tors, eradication of Helicobacter pylori, prokinetic
agents, and fundus-relaxing drugs [1, 3]; however, man-
agement of FD can be challenging mainly due to fre-
quent relapse [3].
Functional dyspepsia is one of the most common
functional disorders affecting the adult population in
Western countries with an estimated prevalence be-
tween 20 and 25% [1], while there are estimates for glo-
bal prevalence as high as 45% [5]. Functional dyspepsia
appears to occur more frequently in females than in
males [5]. The average age of the affected patient popu-
lation seems to be about 45 years, and, although esti-
mates vary, it is clearly more prevalent in those older
than 40 years of age [5]. Although not life-threatening
nor damaging to any organ, FD is a burden for patients
and is associated with excess comorbidity [6, 7]. It also
leads to high costs due to diagnostics and medication,
and can also cause excess work absenteeism and
decreased productivity [6, 7].
Enzynorm®f (manufactured by Nordmark Arzneimit-
tel GmbH & Co. KG, Uetersen, Germany) is a pharma-
ceutical preparation comprising fixed amounts of
pepsin of biological origin and organically bound acid
in the form of amino acid hydrochloride [8]. It is trad-
itionally used as a mild agent for support of gastric
function and to stimulate the stomach’s proteolytic ac-
tivities in FD [8, 9] and has been marketed in Germany
for more than 80 years [10]. The rationale for its pos-
sible effects is that pepsin as, a proteolytic enzyme has
a key role in the initial hydrolysis of ingested proteins
into smaller peptides in the stomach and therefore add-
itional pepsin and acidic components should support
digestion [9]. Despite its long history of usage in pa-
tients with FD, however, there is a lack of scientific data
on the use of Enzynorm®f or other digestive enzyme
preparations that are available for the treatment of FD.
Only some small-scale studies with pancreatic enzymes,
typically showing proteolytic, lipolytic and carboxylic
activities, for treating disorders including FD have been
published [11, 12]. In the absence of any clinical study
data on the use of Enzynorm®f for the treatment of FD,
we have conducted an observational study to evaluate
the effects of this fixed combination of pepsin and
amino acid hydrochloride on the course of symptoms
and tolerability during 6 weeks’ treatment.
Methods
Study design and objectives
This was a non-interventional, observational, post-
marketing surveillance study. The primary objective was to
assess the change of symptoms following treatment with a
fixed combination of pepsin and amino acid hydrochloride
when used as daily standard therapy over a period of ap-
proximately 6 weeks. Secondary objectives were patients’
assessments of the frequency and intensity of their gastro-
intestinal symptoms and tolerability of treatment.
The study was performed in the outpatient clinic of
the department for Natural Medicine of Charité at Im-
manuel Hospital, University Medicine Berlin, Germany,
between January 2012 and December 2013. The study
was brought to patients’ attention by means of advertise-
ments in the local press and on the hospital’s website.
Patients were examined at baseline, after 3 and after
6 weeks of treatment for assessment of symptoms and tol-
erability. In addition, they were contacted by telephone
approximately 1 week after they had started the study.
The study was performed in compliance with Good
Clinical Practice (according to GCP-V, 2004) and all ap-
plicable laws and regulations. Written informed consent
was obtained from all patients. The study design was ap-
proved by the Ethics Committee of Charité, University
Medicine Berlin, Germany, prior to the study. The study
sponsor was Nordmark Arzneimittel GmbH & Co. KG,
Uetersen, Germany.
Patients
The study included male and female patients between 18
and 75 years of age with a diagnosis of acute or chronic
FD, as verified by their medical history. To be included, pa-
tients were required to have had at least 2 of the following
gastrointestinal symptoms present during at least the previ-
ous 4 weeks with at least moderate severity. The latter was
defined as moderately severe and moderately troublesome
on at least 5 days in the prior 2 weeks: bad breath, burping,
nausea, heartburn, feeling of fullness, epigastric pain
(Table 1). Patients were also required to be evaluated ac-
cording to the Rome III criteria for FD [13, 14] prior to in-
clusion (the study was conducted prior to the introduction
of the Rome IV criteria [4]).
In addition to the study treatment, patients continued
their usual therapy for FD during the study. Patients
with contraindications for the study treatment, such as
known allergies against the active ingredients or any of
the excipients, were excluded from the study. Patients
showing alarm symptoms, patients with significant ac-
companying gastrointestinal or other diseases, pregnant
or nursing women were not considered eligible, and
neither were patients with a change in medication over
the last 6 weeks or previous intake of pepsin and amino
acid hydrochloride.
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Treatment
The active constituents of a single Enzynorm®f tablet are
225–250 mg dry extract of porcine gastric mucosa with
proteinases plus 250 mg amino acid hydrochloride from
bovine albumin hydrolysate [8]. Commonly, tablets are
to be swallowed unbroken three times daily before meals
with some liquid. Dosing was left to the judgement of
the physician following the scheme used in patients’
standard care and in accordance with the usage informa-
tion that means 3 × 1 as usual, 3 × 2 as augmented and
up to 20 tablets daily as maximum dosage [8].
Outcome parameters
The primary outcome parameter was the change from
baseline in FD symptoms as evaluated with the Gastro-
intestinal Symptom Score© (GIS©) [15] after 3 and
6 weeks of treatment. The GIS© comprises a validated
questionnaire completed by the healthcare professional
during a face-to-face interview with the patient [15]. It
includes 10 items typically related to FD: epigastric pain/
upper abdominal pain, abdominal cramps, bloating, early
satiety, loss of appetite, sickness, nausea, vomiting,
retrosternal discomfort and acidic eructation/heart-
burn. Intensity of each item is rated on a 5-point Likert
scale (0 = no problem, 1 = mild problem, 2 = moderate
problem, 3 = severe problem and 4 = very severe prob-
lem). With a maximum score of 4 points for each
symptom, the questionnaire can yield a maximum score
of 40, [15]. GIS© has been found to fulfil key criteria
such as reproducibility, responsiveness to change and
validity [15], and is suitable for evaluating the severity
of FD and changes under treatment.
In addition, patients were asked for a subjective evalu-
ation of the treatment effect at the end of treatment.
The following score was used: 1 = very good, 2 = good,
3 = moderate, 4 = no effect. Where patients rated the
efficacy on an intermediate level (e.g., 1.5), values
were allocated to the next higher score for statistical
analyses.
Safety and tolerability measures included recording of
adverse events according to the Medical Dictionary for
Regulatory Activities (MedDRA), as well as physical
examination and measurements of vital signs.
Statistical analysis
A sample size of 100 patients was planned for the study,
although this was not based on a formal statistical power
calculation.
Demographic data were described as means ± standard
deviations. Missing data were not computed. The Wilcoxon
rank sum test and Student’s t-test were both performed
with the results of Wilcoxon rank sum test being used for
tests with N < 40 and those of Student’s t-test when N≥40,
with statistical significance at p ≤ 0.05. All analysis data sets
and statistical outputs were produced using SAS version
9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Quality control (QC)
The study was monitored by an independent Clinical
Monitor. The Clinical Monitor verified Informed Consent,
safety-related data and completeness of the assessments.
The biometrical report, integrated study report, and this
publication were subject to additional QC measures.
Results
Patient demographics
A total of 97 patients were included in the study and
treated with a fixed combination of pepsin and amino
acid hydrochloride. A subgroup of 71 (74.2%) of these
patients met the Rome III criteria for FD. Patients had a
mean age of 58.4 ± 13.9 years and 63.2% were females,
of whom 69.0% were postmenopausal. At baseline, 7.9%
of the patients were smokers, 32.6% former smokers and
59.6% non-smokers; 60.9% of the patients occasionally
consumed alcohol, 19.6% never, 15.2% once or twice per
week and 4.4% daily. Almost all patients (96.8%) had
good general health according to physicians’ judgements.
Mean heart rate was 67.2 ± 6.8 min−1 and systolic
and diastolic blood pressures 127.9 ±16.6 mmHg and
83.8 ± 10.0 mmHg, respectively.
Mean weight was 71.4 ± 13.7 kg, height 170.3 ± 8.5 cm.
The majority (70.5%) reported constant weight during the
Table 1 Study inclusion and exclusion criteria
Demographic inclusion criteria
• Males and females
• Age≥ 18 years to ≤75 years of age
Clinical inclusion criteria
• Acute or chronic functional dyspepsia verifed by medical history
• ≥ 2 of the following gastrointestinal symptoms at moderate severitya
within prior 4 weeks:
○ Bad breath, burping, nausea, heartburn, feeling of fullness, epigastric
pain
• Undergo evaluation according to the Rome III criteria for FD [13, 14]b
Exclusion criteria
• Contraindications to study treatment (e.g., Known allergies to active
ingredients or excipients)
• Presence of alarm symptoms
• Significant accompanying gastrointestinal or other disease
• Pregnancy or nursing of infant(s)
• Patients with changes to medication within prior 6 weeks
• Previous intake of pepsin and amino acid hydrochloride
aDefined as moderately severe and moderately troublesome on ≥5 days in the
prior 2 weeks
bThe study was conducted prior to introduction of the Rome IV criteria [4]
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6 weeks preceding the study, while14.7% claimed gain
(n = 5, 4.9 ± 1.6 kg) or loss (n = 8, 4.7 ± 2.1 kg).
Of the 97 patients included, 72 had GIS© score data
for baseline and after 6 weeks of treatment. Two patients
refused to take the prescribed medication and thus were
not followed-up. Thirty-four patients had full sets of
data at baseline, 3 and 6 weeks of treatment.
Gastrointestinal symptom score
The overall GIS© sum score decreased from 11.6 before
to 7.4 after a treatment period of 6 weeks, a decrease of
4.1 points (p < 0.0001; Table 2) reflecting an improve-
ment of clinical symptomatology. For patients with
GIS© data at 3 and 6 weeks, most of the decrease oc-
curred during the first 3 weeks (Table 2). Changes in in-
dividual GIS© sum scores for all patients (n = 97) are
shown in Fig. 1.
Table 3 provides an overview of the individual GIS©
symptom components at baseline and after 6 weeks.
There were significant decreases in all single symptoms
evaluated, except for nausea and vomiting.
GIS© data were available for 70 of the 71 patients who
fulfilled the Rome III Criteria for FD. The mean baseline
score in this subgroup was 11.1 (± 5.1), after 3 weeks
this had decreased to 8.5 (± 4.6; p = 0.01) and after
6 weeks to 7.4 (±4.1; p < 0.0001). A GIS© score reduc-
tion of ≥50% was observed in 24.0% of patients (6 of 25
available questionnaires) after 3 weeks and in 30.8% (16
of 52 available questionnaires) after 6 weeks.
Patients’ assessment of efficacy
Patients’ self-reported assessments of the effect of
6 weeks of treatment on their symptoms are shown in
Table 4. Most (79.7%) rated their symptoms after treat-
ment as very good, good or moderate.
Tolerability
There were 45 adverse events in 20 patients, for which
either the physician or the study sponsor assumed a po-
tential causality to the study medication. The vast major-
ity of these were gastrointestinal symptoms, potentially
also linked to the underlying FD. Five of these 20 pa-
tients did not change dosage, 1 patient reduced daily
dose, 13 patients stopped the treatment, and 1 patient
ceased medication intake due to presumed lack of effi-
cacy. No serious adverse events were reported.
Other reasons for prematurely discontinuing study
participation included lack of efficacy, leading to with-
drawal by 6 patients (in addition to the 1 above), whilst
another 5 withdrew from the study following freedom
from symptoms, non-compliance with treatment, or
with no reason given.
A comparison of vital signs documented at baseline and
after 6 weeks of treatment showed no changes. Further-
more, there were no differences in abdominal girth mea-
surements between baseline and at the end of treatment.
Discussion
The aim of this observational study was to explore the
effects of a fixed combination of pepsin and amino acid
hydrochloride on symptoms in patients with FD. The
primary outcome was change in GIS© with treatment.
The GIS© sum score as well as the majority of its com-
ponent scores were reduced significantly after 3 weeks
treatment, with further changes observed after 6 weeks.
There were no statistically significant score reductions
for the GIS© vomiting and nausea items; however, few
patients reported these two symptoms and the scores for
these were also very low both before treatment initiation
and after 6 weeks. In addition, in the subgroup of pa-
tients with symptoms meeting the Rome III criteria for
FD, the reduction from baseline in GIS© was significant
after 3 and 6 weeks.
Treatment tolerability in this study was good to moder-
ate, with documented adverse reactions that were mostly
related to gastrointestinal symptoms.
The patient population recruited for this non-
interventional, observational study reflected the typical
patient population with FD, with regard to age and gen-
der [1, 5]. Patients with FD, and those included in this
study, show a variety of different symptoms such as
bloating, early satiety, epigastric pain, nausea, sickness
Table 2 Comparison of mean GIS© sum scores at baseline and after 6 weeks’ treatment
N Mean± Standard deviation (SD) (Minimum – Maximum) Change from baseline
Patients with complete GIS© data for baseline and Week 6
Baseline 72a 11.57 ± 4.8 (4–28) ─
Week 6 72a 7.43 ± 4.55 (0–27.5) −4.14 (p < 0.0001b)
All patients with GIS© data at baseline and Week 3 and/or Week 6
Baseline 94 11.47 ± 5.45 (2–29) ─
Week 3 37 8.36 ± 4.66 (1.5–18) – 3.11 (p = 0.0002)
Week 6 73 7.51 ± 4.57 (0–27.5) −3.96 (p < 0.0001)
aNumber of patients with complete data for V0 and V3
bStatistically significant using Student’s t-test
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and vomiting, retrosternal discomfort, heartburn, loss of
appetite and abdominal pain, with these symptoms are
present either alone or in combination [1–4]. A broad
spectrum of factors have been implicated as causes of
FD, ranging from Helicobacter pylori infection through
inflammation to psychosocial issues [1, 2], and its man-
agement can be challenging once causes such as Helico-
bacter pylori have been excluded [3].
Validation and retrospective studies have previously
shown that GIS© is a reliable and sensitive tool for the
follow-up of FD-related symptoms [15, 16], enabling
accurate differentiation of non-responders and re-
sponders. Furthermore, scores documented by gastro-
enterologists and general practitioners showed strong
correlations, and a strong correlation to the symptom-
specific components of the validated Nepean Dyspepsia
Index has also been shown [15, 17]. With regards to in-
terpretation of GIS©, a sum score of ≤10 corresponds
to mild symptoms, where some symptoms may not be
present at all and are thus impossible to improve [15,
16]. In this study, the mean baseline overall score was
>10, but decreased to <10 for the whole study popula-
tion as well as the large Rome III subgroup (74.2%).
Placebo response in this field may affect up to 20% of
patients [18, 19]; however, in this study, FD patients
meeting the Rome III criteria, for example, improve-
ments in GIS© were observed in about one third of pa-
tients after 6 weeks.
The fixed combination of pepsin and amino acid
hydrochloride evaluated in the present study has trad-
itionally used as a mild agent for support of gastric
function in FD [8, 9]. Its precise mechanism of action
is, however, unknown, although it is thought that the
combination of pepsin and the acidic component
should support digestion by aiding the stomach’s pro-
teolytic activities [8, 9]. Further studies using in vitro
Fig. 1 Comparison of individual GIS© sum scores (n = 97) at baseline, at the interim visit (21 ± 3 days), and at the end of treatment visit (42 ± 3 days)
for patients with any available GIS© data
Table 3 Specific Symptom scores of GIS© at baseline and after 6 weeks of treatment
Symptom Score at baseline [Mean± SD (N)] Score at 6 weeks [Mean± SD (N)] P: Difference to baseline score
Epigastric pain/ upper abdominal pain 1.65 ± 1,04 (94) 1.12 ± 0,97 (73) < 0.0001
Abdominal cramps 1.23 ± 1.18 (94) 0.74 ± 0.89 (72) 0.003
Bloating 2.12 ± 1.08 (94) 1.32 ± 1.08 (73) < 0.0001
Early satiety 1.06 ± 1.00 (94) 0.81 ± 0.90 (72) 0.006
Loss of appetite 0.74 ± 1.01 (93) 0.44 ± 0.83 (73) 0.042
Sickness 0.98 ± 1.10 (94) 0.72 ± 0.95 (73) 0.017
Nausea 0.27 ± 0.74 (94) 0.15 ± 0.57 (73) 0.35
Vomiting 0.22 ± 0.72 (94) 0.10 ± 0.48 (73) 0.51
Retrosternal discomfort 1.40 ± 1.00 (94) 0.95 ± 0.88 (73) 0.019
Acidic eructation/ Heartburn 1.80 ± 1.12 (94) 1.20 ± 1.03 (73) < 0.0001
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or animal models could help shed light on the mech-
anism of action.
Limitations
Firstly, this study had an observational design and was
not a randomised clinical trial, the strength of the evi-
dence obtained should therefore be weighted accord-
ingly. Patients with acute or chronic FD symptoms were
included and perhaps a larger study is warranted where
these two groups can be evaluated separately. The study
treatment was administered to individual patients at dif-
ferent dosages according to their treating physicians’
judgement. Therefore, although doses were within a
dose range in the usage information [8], there may have
been variations between patients in the dosages taken
for a given level of symptoms. Finally, only 72 of 97 pa-
tients completed the study, with patients discontinuing
mostly because of gastrointestinal symptoms, perceived
as insufficient treatment and/or even possible worsening.
Patients with a long history FD should be advised in fu-
ture studies as well as in clinical practice, that their con-
dition needs long term treatment as the beneficial
effects may not become apparent for several weeks.
Conclusions
The results of this observational study suggest that a
fixed combination of pepsin and amino acid hydrochlor-
ide may be efficacious for the treatment of patients with
FD. Good to moderate tolerability of this treatment is
suggested. These findings should be further explored
and evaluated in randomised controlled clinical trials.
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